Tag Archives: Cancer

FDA approved PEGylated drug

To date, eleven PEGylated proteins, antibody fragments, oligonucleotides, and small molecules have been approved by FDA are on the market, including PEGylated bovine adenosine deaminase: pegademase bovine (Adagen); and PEGylated l-asparaginase: pegaspargase (Oncaspar); PEGylated products of interferon-alpha (IFN-alpha): peginterferon-2b (PegIntron) … Continue reading

Posted in Blogs, PEGylated Products on Market, pegylation, PEGylation Success Stories | Tagged , , , | 1 Comment

Can a PEGylated protein be ever considered a Biosimilar drug?

In March 2015, the FDA approved the first biosimilar drug for use in the United States. The drug called Zarxio, produced by Sandoz, is used to help prevent infections in cancer patients receiving chemotherapy, and it is a biosimilar alternative … Continue reading

Posted in Biologic, Biosimilar, Blogs, cancer, chemotherapy, pegylation, PEGylation Reagents | Tagged , , , , , , | Leave a comment

High-density lipoprotein mimetic drug delivery systems for cancer, cardiovascular diseases

Nanolipoprotein particles (NLPs), which are mimetics of naturally occurring high-density lipoproteins (HDLs) present in the human body have been suggested as a new delivery platform for a range of therapeutics for cancer chemotherapy, heart disease, and infectious diseases. FDA approved … Continue reading

Posted in PEG Derivatives, PEGylation Reagents | Tagged , , , , , , | Leave a comment

Designer Proteins Trigger Cell Death – a new cancer therapy?

Researchers from University of Washington and the Howard Hughes Medical Institute use an innovative computational design approach coupled with in-vitro-targeted evolution to produce a potent polypeptide inhibitor that triggers apoptosis of virus-infected cancer cells, suppresses tumor growth and extends survival … Continue reading

Posted in PEG Derivatives, PEGylation Reagents, PEGylation Success Stories | Tagged , , , | 1 Comment